Webb22 apr. 2024 · The warrants will be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The closing of the offering is expected to take place on or about April 26, 2024, subject to the satisfaction of customary closing conditions. WebbSalarius Pharmaceuticals shares outstanding from 2015 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares. Compare SLRX With Other Stocks From: To: Zoom:
SLRX - Salarius Pharmaceuticals, Inc. Stock Price and Quote
Webb11 dec. 2024 · The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to a registration statement on Form S-1 ... SLRX. … WebbSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. CEO David J. Arthur Employees 12 Headquarters Houston, Texas Founded 2014 port of lyttelton arrivals
Warrantskolan SEB
WebbView the latest Salarius Pharmaceuticals Inc. (SLRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Webb1 aug. 2024 · A company might sell a stock warrant with an expiration date that is up to 15 years away. Options, on the other hand, expire either in three, six, nine months, 1 year, or … Webb11 dec. 2024 · Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat - Salarius Pharmaceuticals (NASDAQ:SLRX) - Benzinga 396.38 1.07%... port of mackay induction